Group 1

Rapid innovation is also critical to our mission

At Aerion Bioscience, we’re on the forefront of transforming lung cancer detection. Our breakthrough 6-protein biomarker panel has not only shown promise in preliminary clinical testing for early detection of lung cancer, furthermore we’ve successfully tested it in a second clinical group. Our focus for the near future is clear and ambitious – we’re expanding our tests to include a wider range of lung cancer samples, healthy individuals, and even other lung conditions. This broad testing is crucial for us to understand if our markers can not only detect lung cancer but also distinguish its various stages, evaluate its aggressiveness, and possibly identify other lung diseases like chronic obstructive pulmonary disease.